Common Name |
Clindamycin
Description |
Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Structure |
MOLSDF3D-SDFPDBSMILESInChI View 3D Structure
Synonyms |
Value |
Source |
7(S)-chloro-7-DeoxylincomycinChEBI
7-CDLChEBI
CleocinChEBI
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranosideChEBI
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-a-D-galacto-octopyranosideGenerator
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranosideGenerator
Clindamycin phosphateHMDB
7 chloro 7 DeoxylincomycinMeSH
Clindamycin monohydrochloride, monohydrateMeSH
Hydrochloride, clindamycinMeSH
Monohydrate clindamycin monohydrochlorideMeSH
7-chloro-7-DeoxylincomycinMeSH
ChlolincocinMeSH
Clindamycin hydrochlorideMeSH
Monohydrochloride, clindamycinMeSH
Monohydrochloride, monohydrate clindamycinMeSH
ChlorlincocinMeSH
Clindamycin monohydrochlorideMeSH
Dalacin CMeSH
Chemical Formlia |
C18H33ClN2O5S
Average Molecliar Weight |
424.983
Monoisotopic Molecliar Weight |
424.179870573
IUPAC Name |
(2S,4R)-N-{2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylslifanyl)oxan-2-yl]propyl}-1-methyl-4-propylpyrrolidine-2-carboxamide
Traditional Name |
clindamycin
CAS Registry Number |
18323-44-9
SMILES |
CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
InChI Identifier |
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1
InChI Key |
KDLRVYVGXIQJDK-NOWPCOIGSA-N
Chemical Taxonomy |
Description |
This compound belongs to the class of chemical entities known as proline and derivatives. These are compounds containing proline or a derivative thereof resliting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom |
Chemical entities
Super Class |
Organic compounds
Class |
Organic acids and derivatives
Sub Class |
Carboxylic acids and derivatives
Direct Parent |
Proline and derivatives
Alternative Parents |
Alpha amino acid amides
Thioglycosides
Pyrrolidinecarboxamides
Monosaccharides
N-alkylpyrrolidines
Oxanes
Monothioacetals
Trialkylamines
Secondary carboxylic acid amides
Secondary alcohols
Azacyclic compounds
Slifenyl compounds
Oxacyclic compounds
Polyols
Organochlorides
Organic oxides
Alkyl chlorides
Hydrocarbon derivatives
Carbonyl compounds
Organopnictogen compounds
Substituents |
Proline or derivatives
Alpha-amino acid amide
Glycosyl compound
S-glycosyl compound
Pyrrolidine carboxylic acid or derivatives
Pyrrolidine-2-carboxamide
Monosaccharide
Oxane
N-alkylpyrrolidine
Monothioacetal
Pyrrolidine
Carboxamide group
Secondary alcohol
Secondary carboxylic acid amide
Tertiary amine
Tertiary aliphatic amine
Slifenyl compound
Organoheterocyclic compound
Azacycle
Polyol
Oxacycle
Organic nitrogen compound
Organoslifur compound
Organooxygen compound
Organonitrogen compound
Organochloride
Organohalogen compound
Alkyl chloride
Alcohol
Organic oxygen compound
Carbonyl group
Amine
Organopnictogen compound
Organic oxide
Alkyl halide
Hydrocarbon derivative
Aliphatic heteromonocyclic compound
Molecliar Framework |
Aliphatic heteromonocyclic compounds
External Descriptors |
organochlorine compound (CHEBI:3745 )
pyrrolidinecarboxamide (CHEBI:3745 )
carbohydrate-containing antibiotic (CHEBI:3745 )
S-glycosyl compound (CHEBI:3745 )
Ontology |
Status |
Expected but not Quantified
Origin |
Drug
Biofunction |
Anti-Bacterial Agents
Lincomycins
Protein Synthesis Inhibitors
Application |
Pharmaceutical
Cellliar locations |
Cytoplasm
Membrane
Physical Properties |
State |
Solid
Experimental Properties |
Property |
Value |
Reference |
Melting Point142 °C (hydrochloride salt)Not Available
Boiling PointNot AvailableNot Available
Water Solubility3.10e+00 g/LNot Available
LogP1.6Not Available
Predicted Properties |
Property |
Value |
Source |
Water Solubility3.1 mg/mLALOGPS
logP1.76ALOGPS
logP1.04ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)12.16ChemAxon
pKa (Strongest Basic)7.55ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area102.26 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity105.72 m3·mol-1ChemAxon
Polarizability44.49 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rlie of FiveYesChemAxon
Ghose FilterYesChemAxon
Vebers RlieYesChemAxon
MDDR-like RlieYesChemAxon
Spectra |
Spectra |
Spectrum Type |
Description |
Splash Key |
|
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0109100000-37670022935f2d8b670bView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0000900000-93a1722f96f472875c4aView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0901200000-390e3523bed2d5f929e0View in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0900000000-70466cfb7e0692d073a0View in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0900000000-6bd03c57dadca1290f64View in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0900000000-cd434c8b18380d1a324eView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-2900000000-6c05f4179cb5bb39be52View in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0000900000-94150d67f34bea64e6adView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0901200000-8eaa211b21b0d6193e5eView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0900000000-734d71b0a8760cca4fa1View in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0900000000-dcfb0de2ed3f9a132d0eView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0900000000-19e29af7279013b527bcView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-2900000000-b410c4ec9eb02ede33baView in MoNA
LC-MS/MS |
LC-MS/MS Spectrum – LC-ESI-ITFT , positivesplash10-004i-0109100000-41472a595b36c3659456View in MoNA
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available
Predicted LC-MS/MS |
Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available
Biological Properties |
Cellliar Locations |
Cytoplasm
Membrane
Biofluid Locations |
Blood
Urine
Tissue Location |
Not Available
Pathways |
Name |
SMPDB Link |
KEGG Link |
Clindamycin PathwaySMP00249Not Available
Normal Concentrations |
Biofluid |
Status |
Age |
Condition |
Reference |
Details |
BloodExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01190
21059682
details
UrineExpected but not Quantified Not AvailableNot AvailableTaking drug identified by DrugBank entry DB01190
21059682
details
|
Abnormal Concentrations |
|
Not Available
Predicted Concentrations |
|
Biofluid |
Original age |
Original condition |
Blood0-2 uMAdlit (>18 years old)BothNormalPredicted based on drug qualities
Blood0-1 umol/mmol creatinineAdlit (>18 years old)BothNormalPredicted based on drug qualities
Associated Disorders and Diseases |
Disease References |
None
Associated OMIM IDs |
None
External Links |
DrugBank ID |
DB01190
DrugBank Metabolite ID |
Not Available
Phenol Explorer Compound ID |
Not Available
Phenol Explorer Metabolite ID |
Not Available
FoodDB ID |
Not Available
KNApSAcK ID |
Not Available
Chemspider ID |
27005
KEGG Compound ID |
C06914
BioCyc ID |
Not Available
BiGG ID |
Not Available
Wikipedia Link |
Clindamycin
NuGOwiki Link |
HMDB15321
Metagene Link |
HMDB15321
METLIN ID |
Not Available
PubChem Compound |
29029
PDB ID |
Not Available
ChEBI ID |
3745
Product: Cysteine Protease inhibitor (hydrochloride)
References |
Synthesis Reference |
Not Available |
Material Safety Data Sheet (MSDS) |
Not Available |
General References |
- Lamont RF: Can antibiotics prevent preterm birth–the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73. [PubMed:15715599 ]
- Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC: Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. [PubMed:2751277 ]
- Klempner MS, Styrt B: Clindamycin uptake by human neutrophils. J Infect Dis. 1981 Nov;144(5):472-9. [PubMed:6171600 ]
- Daum RS: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007 Jul 26;357(4):380-90. [PubMed:17652653 ]
|
Enzymes
- General function:
- Involved in monooxygenase activity
- Specific function:
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
- Gene Name:
- CYP3A4
- Uniprot ID:
- P08684
- Molecular weight:
- 57255.585
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
PMID: 11913557